Niushen Zhang, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Zhang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A122840 · Current
Licensed to practise in California · since 2012 · expires 2028-05-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$19,632
Medicare paid this office $19,632 for 105 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 40 | $7,189 | $87 |
| New patient visit (60+ min) | 35 | $4,908 | $140 |
| Long return visit (40+ min) | 19 | $2,181 | $115 |
| Return visit (30+ min) | 16 | $1,980 | $124 |
| Return visit (30+ min) | 13 | $1,140 | $76 |
Who their Medicare patients are
105 Original Medicare patients in 2024. Average age 68 · Women 73% · Also on Medicaid 27% · Health risk score 1.33. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 63% · Depression 29% · Diabetes 22% · Coronary heart disease 18% · COPD 13% · Cancer 12% · Chronic kidney disease 11% · Atrial fibrillation 10%.
The office billed $108,980, Medicare allowed $28,219 and paid $19,632; for 203 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 105 | 203 | 68 | 1.33 | $108,980 | $19,632 |
| 2023 | 91 | 167 | 67 | 1.13 | $87,975 | $15,122 |
| 2022 | 116 | 238 | 67 | 0.99 | $125,739 | $22,904 |
| 2021 | 86 | 119 | 68 | 1.18 | $78,283 | $13,298 |
| 2020 | 97 | 160 | 66 | 1.25 | $101,220 | $13,640 |
| 2019 | 126 | 282 | 65 | 1.05 | $145,286 | $25,250 |
| 2018 | 99 | 219 | 64 | 1.03 | $109,976 | $20,433 |
| 2017 | 113 | 282 | 65 | 1.17 | $169,294 | $23,378 |
| 2016 | 56 | 118 | 64 | 1.07 | $68,878 | $10,992 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 40 | $5,968 | $93 |
| New patient visit (60+ min) | 28 | $4,001 | $143 |
| Return visit (30+ min) | 22 | $1,914 | $83 |
| Long return visit (40+ min) | 12 | $1,355 | $113 |
2022: 5 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 29 | $7,346 | $98 |
| New patient visit (60+ min) | 39 | $6,299 | $162 |
| Long return visit (40+ min) | 32 | $4,263 | $125 |
| Return visit (30+ min) | 26 | $2,227 | $80 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 15 | $1,603 | $64 |
2021: 3 services
| New patient visit (60+ min) | 35 | $5,648 | $161 |
| Long return visit (40+ min) | 24 | $3,405 | $126 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 22 | $2,864 | $102 |
2020: 5 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 29 | $4,066 | $90 |
| New patient visit (60+ min) | 15 | $2,246 | $150 |
| Long return visit (40+ min) | 21 | $1,961 | $89 |
| New patient visit (45+ min) | 14 | $1,568 | $112 |
| Return visit (30+ min) | 20 | $1,542 | $67 |
2019: 5 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 58 | $13,844 | $97 |
| New patient visit (60+ min) | 39 | $5,217 | $134 |
| Long return visit (40+ min) | 29 | $2,916 | $97 |
| Return visit (30+ min) | 14 | $1,235 | $69 |
| Short return visit (20+ min) | 13 | $561 | $40 |
2018: 5 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 33 | $6,304 | $90 |
| New patient visit (60+ min) | 26 | $3,497 | $135 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 24 | $2,770 | $107 |
| Long return visit (40+ min) | 24 | $2,600 | $93 |
| New patient visit (60+ min) | 11 | $1,656 | $151 |
2017: 7 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 60 | $12,975 | $98 |
| New patient visit (60+ min) | 16 | $2,405 | $150 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 13 | $2,151 | $77 |
| New patient visit (45+ min) | 16 | $1,583 | $99 |
| Long return visit (40+ min) | 12 | $1,121 | $86 |
| Return visit (30+ min) | 12 | $988 | $71 |
| Injection of trigger points, 3 or more muscles | 12 | $946 | $28 |
2016: 3 services
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 30 | $4,685 | $106 |
| New patient visit (60+ min) | 14 | $1,871 | $134 |
| Long return visit (40+ min) | 15 | $1,585 | $99 |
Medicaid work
$105,370 in 2024
Medicaid paid $105,370 for 327 billed services this clinician did in 2024, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Botox | 140 | $91,251 |
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 187 | $14,119 |
| 2024 | 327 | 2 | 24 | $105,370 |
| 2022 | 12 | 1 | 12 | $1,189 |
| 2019 | 25 | 1 | 13 | $1,433 |
See the largest Medicaid services in earlier years
2022
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 12 | $1,189 |
2019
| Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine) | 25 | $1,433 |
Drugs they prescribed that Part D paid
$71,800
Pharmacies billed $71,800 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 157) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
78 generic and 79 brand-name prescriptions · $71,800 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Qulipta | None | 19 | $22,639 | $1,192 |
| Ubrelvy | None | 13 | $13,002 | $1,000 |
| Aimovig | Migraine | 11 | $8,196 | $745 |
| Emgality | Migraine | 11 | $7,109 | $646 |
| Gabapentin | None | 21 | $221 | $11 |
Year by year
| 2024 | 157 | 34 | 0% (0) | 50% | $71,800 |
| 2023 | 190 | 40 | 0% (0) | 43% | $84,003 |
| 2022 | 128 | 28 | 0% (0) | 42% | $49,365 |
| 2021 | 79 | 22 | 0% (0) | 18% | $12,903 |
| 2020 | 141 | 26 | 0% (0) | 33% | $36,676 |
| 2019 | 157 | 32 | 0% (0) | 20% | $28,066 |
| 2018 | 157 | 31 | 0% (0) | None | $7,943 |
| 2017 | 127 | 22 | 0% (0) | 9% | $6,754 |
| 2016 | 52 | 17 | 0% (0) | None | $1,709 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Qulipta | None | 19 | $25,234 | $1,328 |
| Nurtec Odt | None | 15 | $15,567 | $1,038 |
| Emgality | Migraine | 20 | $15,043 | $752 |
| Aimovig | Migraine | 11 | $8,788 | $799 |
| Sumatriptan | None | 14 | $2,944 | $210 |
| Rizatriptan | None | 12 | $367 | $31 |
| Gabapentin | None | 27 | $352 | $13 |
| Promethazine | None | 15 | $239 | $16 |
2022: 4 drugs
| Emgality | Migraine | 23 | $17,051 | $741 |
| Rizatriptan | None | 15 | $884 | $59 |
| Promethazine | None | 12 | $170 | $14 |
| Gabapentin | None | 17 | $125 | $7 |
2021: 2 drugs
| Rizatriptan | 11 | $999 | $91 |
| Gabapentin | 16 | $178 | $11 |
2020: 4 drugs
| Emgality | Migraine | 36 | $25,480 | $708 |
| Rizatriptan | None | 18 | $962 | $53 |
| Gabapentin | None | 24 | $257 | $11 |
| Tizanidine | None | 13 | $87 | $7 |
2019: 6 drugs
| Emgality | Migraine | 12 | $9,971 | $831 |
| Ajovy | None | 13 | $7,278 | $560 |
| Rizatriptan | None | 14 | $532 | $38 |
| Gabapentin | None | 24 | $304 | $13 |
| Tizanidine | None | 19 | $257 | $14 |
| Promethazine | None | 11 | $44 | $4 |
2018: 5 drugs
| Rizatriptan | 22 | $1,049 | $48 |
| Tizanidine | 29 | $370 | $13 |
| Topiramate | 17 | $266 | $16 |
| Gabapentin | 17 | $217 | $13 |
| Verapamil | 14 | $99 | $7 |
2017: 4 drugs
| Namenda Xr | 12 | $4,650 | $387 |
| Gabapentin | 18 | $267 | $15 |
| Tizanidine | 20 | $223 | $11 |
| Topiramate | 17 | $124 | $7 |
2016: 1 drug
| Topiramate | 13 | $138 | $11 |
Money from drug and device companies
$39 in 2019
A payment is not proof that care is biased.
| Eli Lilly and | None | $39 | 1 payment
|
See the published payment
| Eli Lilly and | Meals · 2019-07-10 | None | $39 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1447559695
- Licence
- CA A122840California A122840: Current · expires 2028-05-31
- Trained
- New York University School of Medicine, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084P2900X (2084P2900X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-03-26
- NPI last updated
- 2023-11-09
- NPI record certified
- 2023-11-09
This is when the NPI record was last certified, not a medical board exam.